Heartflow Inc (NASDAQ:HTFL) Reports Strong Revenue Beat but Widens Loss; Shares Decline After Hours
HEARTFLOW INC (HTFL) released its fourth-quarter and full-year 2025 financial results after the market close on March 18, 2026, delivering a significant top-line beat against analyst expectations while its adjusted loss per share was narrower than feared. Despite the positive earnings surprise, the company's shares traded lower in the after-hours session.
Earnings and Revenue Versus Estimates
The company’s performance against Wall Street’s projections for the fourth quarter presents a mixed but generally positive picture:
- Revenue: Heartflow reported Q4 revenue of $49.1 million, surpassing the analyst consensus estimate of $47.4 million. This represents a 40% increase year-over-year.
- Earnings Per Share (Non-GAAP): The company reported a non-GAAP net loss per share of ($0.12), which was better than the estimated loss of ($0.17).
For the full year 2025, Heartflow posted revenue of $176.0 million, also reflecting 40% growth compared to 2024.
Market Reaction and Price Action
Following the earnings release, Heartflow’s stock experienced a decline in after-market trading. This reaction suggests that investors may be focusing on elements beyond the headline beats, such as the company’s ongoing losses and its forward guidance.
The recent stock performance shows:
- A decline of approximately 7.3% in after-hours trading following the report.
- Relatively flat performance over the past week and month, indicating the market was in a holding pattern ahead of the earnings announcement.
Key Highlights from the Press Release
Beyond the earnings figures, management highlighted several operational and strategic milestones:
- Strong Growth Drivers: The year-over-year revenue increase was primarily driven by higher U.S. volume for its flagship FFRCT Analysis.
- Improving Profitability Metrics: The company achieved record gross margins, with Q4 non-GAAP gross margin expanding to 79.9%, up from 75.3% a year ago. Management attributed this to increased volume and improved productivity from AI efficiency initiatives.
- Balance Sheet Strength: Heartflow ended the year with a robust cash position of $280.2 million in cash, cash equivalents, and investments, providing a substantial runway to fund operations.
- Commercial Progress: The U.S. installed base grew to 1,465 accounts, with 489 accounts now using its Plaque Analysis product. A key development was the announcement that Aetna began coverage for Plaque Analysis, bringing total U.S. covered lives for the product to approximately 75%.
Forward Outlook and Analyst Comparisons
Heartflow provided formal guidance for 2026, projecting total revenue between $218 million and $222 million, which implies year-over-year growth of 24% to 26%. This outlook appears slightly more conservative than the current analyst consensus sales estimate of $216.8 million for the full year.
The company also guided for a non-GAAP gross margin of 80% to 81%, indicating an expectation to maintain the improved profitability achieved in recent quarters. For the upcoming first quarter of 2026, analysts are currently estimating a loss per share of ($0.20) on revenue of $47.8 million.
Conclusion
Heartflow’s Q4 results demonstrate continued strong commercial execution and impressive revenue growth, comfortably exceeding analyst forecasts. The improvement in gross margins and the solidification of its balance sheet are clear positives. However, the market’s initial negative reaction highlights the ongoing challenge of reconciling robust growth with persistent net losses. Investors will likely monitor the company’s progress toward profitability and its ability to meet its 2026 revenue guidance in the coming quarters.
For a detailed look at Heartflow’s historical earnings and future analyst projections, you can review the earnings history and estimates & forecasts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial advice, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.